Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage

Hiam Chemaitelly (), Houssein H. Ayoub, Peter Coyle, Patrick Tang, Hadi M. Yassine, Hebah A. Al-Khatib, Maria K. Smatti, Mohammad R. Hasan, Zaina Al-Kanaani, Einas Al-Kuwari, Andrew Jeremijenko, Anvar Hassan Kaleeckal, Ali Nizar Latif, Riyazuddin Mohammad Shaik, Hanan F. Abdul-Rahim, Gheyath K. Nasrallah, Mohamed Ghaith Al-Kuwari, Adeel A. Butt, Hamad Eid Al-Romaihi, Mohamed H. Al-Thani, Abdullatif Al-Khal, Roberto Bertollini and Laith J. Abu-Raddad ()
Additional contact information
Hiam Chemaitelly: Cornell University
Houssein H. Ayoub: Qatar University
Peter Coyle: Hamad Medical Corporation
Patrick Tang: Sidra Medicine
Hadi M. Yassine: Qatar University
Hebah A. Al-Khatib: Qatar University
Maria K. Smatti: Qatar University
Mohammad R. Hasan: Sidra Medicine
Zaina Al-Kanaani: Hamad Medical Corporation
Einas Al-Kuwari: Hamad Medical Corporation
Andrew Jeremijenko: Hamad Medical Corporation
Anvar Hassan Kaleeckal: Hamad Medical Corporation
Ali Nizar Latif: Hamad Medical Corporation
Riyazuddin Mohammad Shaik: Hamad Medical Corporation
Hanan F. Abdul-Rahim: Qatar University
Gheyath K. Nasrallah: Qatar University
Mohamed Ghaith Al-Kuwari: Primary Health Care Corporation
Adeel A. Butt: Cornell University
Hamad Eid Al-Romaihi: Ministry of Public Health
Mohamed H. Al-Thani: Ministry of Public Health
Abdullatif Al-Khal: Hamad Medical Corporation
Roberto Bertollini: Ministry of Public Health
Laith J. Abu-Raddad: Cornell University

Nature Communications, 2022, vol. 13, issue 1, 1-11

Abstract: Abstract There is significant genetic distance between SARS-CoV-2 Omicron (B.1.1.529) variant BA.1 and BA.2 sub-lineages. This study investigates immune protection of infection with one sub-lineage against reinfection with the other sub-lineage in Qatar during a large BA.1 and BA.2 Omicron wave, from December 19, 2021 to March 21, 2022. Two national matched, retrospective cohort studies are conducted to estimate effectiveness of BA.1 infection against reinfection with BA.2 (N = 20,994; BA.1-against-BA.2 study), and effectiveness of BA.2 infection against reinfection with BA.1 (N = 110,315; BA.2-against-BA.1 study). Associations are estimated using Cox proportional-hazards regression models after multiple imputation to assign a sub-lineage status for cases with no sub-lineage status (using probabilities based on the test date). Effectiveness of BA.1 infection against reinfection with BA.2 is estimated at 94.2% (95% CI: 89.2–96.9%). Effectiveness of BA.2 infection against reinfection with BA.1 is estimated at 80.9% (95% CI: 73.1–86.4%). Infection with the BA.1 sub-lineage appears to induce strong, but not full immune protection against reinfection with the BA.2 sub-lineage, and vice versa, for at least several weeks after the initial infection.

Date: 2022
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (3)

Downloads: (external link)
https://www.nature.com/articles/s41467-022-32363-4 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-32363-4

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-022-32363-4

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().